Olanzapine long-acting injection: A review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Bushe, Chris J ^a   Falk, Deborah ^b   Anand, Ernie ^b   Casillas, Marta ^c   Perrin, Elena ^d   Chhabra Khanna, Rashna ^b   Detke, Holland C ^b  

^a Eli Lilly   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c ELI LILLY AND COMPANY   (Spain)

^d Eli Lilly   (France)

Author keywords

Depot antipsychotic; Olanzapine; Olanzapine long acting injection; Olanzapine pamoate; Post injection delirium sedation syndrome; Schizophrenia

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ANESTHESIA COMPLICATION; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONFUSION; DELIRIUM; DISORIENTATION; DIZZINESS; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSARTHRIA; FATALITY; HOSPITAL DEPARTMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; POST INJECTION DELIRIUM SEDATION SYNDROME; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; ADMINISTRATION AND DOSAGE; ADULT; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; SYNDROME; THERAPEUTIC USE; UNCONSCIOUSNESS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DELIRIUM; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DYSARTHRIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; SYNDROME; UNCONSCIOUSNESS;

EID: 84926621902     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-015-0450-9     Document Type: Article

References (18)

1. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-9.
2. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1-46.
3. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-9.
4. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69:790-9.
5. McDonnell D, Andersen S, Detke H, Zhao F, Watson S. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights: Psychiatry. 2011;3:37-47.
6. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases. BMC Psychiatry. 2010;10:43.
7. Eli Lilly and Company. Zyprexa Relprevv United States Prescribing Information. 2011 [ http://pi.lilly.com/us/zyprexa_relprevv.pdf ].
8. European Medicines Agency. Summary of product characteristics for ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection. 2014. [ https://www.medicines.org.uk/emc/medicine/21361 ] (Accessed 26 March, 2015).
9. McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. II: investigations of mechanism. BMC Psychiatry. 2010;10:45.
10. Cummings JL, Barritt CF, Horan M. Delusions induced by procaine penicillin: case report and review of the syndrome. Int J Psychiatry Med. 1987;116:163-8.
11. Downham II TF, Cawley RA, Salley SO, Dal Santo G. Systemic toxic reactions to procaine penicillin G. Sex Transm Dis. 1978;5:4-9.
12. Institute for Safe Medication Practices. ISMP medication safety alert: action needed to prevent serious tissue injury with IV promethazine. 2006. [ http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp ] (Accessed 26 March, 2015).
13. Sen S, Chini EN, Brown MJ. Complications after unintentional intra-arterial injection of drugs: risks, outcomes, and management strategies. Mayo Clin Proc. 2005;80:783-95.
14. US Food and Drug Administration. FDA drug safety communication: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate). Safety Announcement. 2013. [ http://www.fda.gov/drugs/drugsafety/ucm356971.htm ] (Accessed 26 March, 2015).
15. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23:43-51.
16. Saar E, Beyer J, Gerostamoulos D, Drummer OH. The time-dependant post-mortem redistribution of antipsychotic drugs. Forensic Sci Int. 2012;222:223-7.
17. McDonnell DP, Detke HC, Falk DM, Shatapathy CC. Olanzapine concentrations collected post-mortem in patients treated with olanzapine long-acting injection. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S489-90.
18. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration: your report can make a difference. J Gen Intern Med. 2003;18:57-60.